Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

But the more we find out about Ozempic and related drugs, the more it seems to be the first time that I’ve been proved wrong ...

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...

Stanford researchers have discovered BRP, a naturally occurring peptide that suppresses appetite and promotes weight loss, ...

(Reuters) -Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, so long as the FDA considered them in shortage.

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.